Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Boehringer Ingelheim
Merck
Mallinckrodt
Johnson and Johnson

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,820,186

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,820,186 protect, and when does it expire?

Patent 7,820,186 protects EPIDUO and is included in one NDA.

This patent has thirty-three patent family members in twenty-two countries.

Summary for Patent: 7,820,186
Title:Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
Abstract:Dermatological/cosmetic gel compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise (i) at least one retinoid, (ii) dispersed benzoyl peroxide and (iii) at least one pH-independent gelling agent, formulated into (iv) a physiologically acceptable medium therefor.
Inventor(s): Orsoni; Sandrine (Mandelieu, FR), Willcox; Nathalie (Le Rouret, FR)
Assignee: Galderma Research & Development (FR)
Application Number:10/326,389
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,820,186
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 7,820,186

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp EPIDUO adapalene; benzoyl peroxide GEL;TOPICAL 022320-001 Dec 8, 2008 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,820,186

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France01 16747Dec 21, 2001

International Family Members for US Patent 7,820,186

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 038026   Start Trial
Austria 347354   Start Trial
Australia 2002364437   Start Trial
Australia 2008246274   Start Trial
Brazil 0214264   Start Trial
Brazil PI0214264   Start Trial
Canada 2466321   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
AstraZeneca
Harvard Business School
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.